Serum prealbumin as a predictor of adverse outcomes in patients with heart failure: a systematic review and meta-analysis

Biomark Med. 2022 May;16(7):569-575. doi: 10.2217/bmm-2021-1065. Epub 2022 Mar 29.

Abstract

Aim: To evaluate the association of serum prealbumin level with adverse outcomes in heart failure (HF) patients by conducting a meta-analysis. Methods: A comprehensive literature search was conducted in both international and Chinese databases to identify the cohort studies that reported the association of serum prealbumin level with all-cause mortality and composite endpoints of death/heart failure readmission in HF patients. Results: Eight studies involving 2439 patients were eligible. Low prealbumin level was associated with higher risk of all-cause mortality (adjusted risk ratio [RR] 1.89; 95% CI: 1.35-2.65) and composite endpoints (adjusted RR 3.08; 95% CI: 1.43-6.64). Conclusions: Low serum prealbumin level may be an independent predictor of all-cause mortality/heart failure readmission in HF patients.

Keywords: all-cause mortality; heart failure; meta-analysis; prealbumin; readmission.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Cohort Studies
  • Heart Failure* / diagnosis
  • Humans
  • Prealbumin* / analysis

Substances

  • Prealbumin